The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-world study with a large population

鼻咽癌 医学 肿瘤科 体积热力学 内科学 人口 小学(天文学) 放射科 环境卫生 放射治疗 物理 天文 量子力学
作者
Xiaohui Wang,Nan Huang,Pui Lam Yip,Jing Wang,Runda Huang,Zhuang Sun,Dehua Kang,Qian He,Xiaowu Deng,Chong Zhao,Melvin L.K. Chua,Fei Han
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:194: 110154-110154 被引量:5
标识
DOI:10.1016/j.radonc.2024.110154
摘要

Abstract

Background and purpose

The delineation of clinical target volume (CTV) for primary nasopharyngeal carcinoma (NPC) is currently controversial and the international guideline still recommend a uniform border for CTV regardless of the tumor extent. We conducted this prospective, real-world study to evaluate the clinical outcomes of our individualized CTV delineation method based on distance plus substructures.

Materials and Methods

We preliminarily investigated the local extension patterns of NPC on 354 newly diagnosed patients and defined the structures surrounding the nasopharynx as Level-1 to Level-4 substructures stratified by the risk of invasion. We then enrolled patients with newly diagnosed NPC without distant metastasis to investigate our individualized CTV delineation protocol. All patients received intensity modulated radiotherapy. CTV1 and CTV2 were prescribed doses of 60 Gy and 54 Gy in 30∼33 fractions. The primary endpoint was local recurrence-free survival (LRFS); secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. The local failure patterns were also analyzed.

Results

From January 2008 to December 2012 and from January 2013 to September 2019, 356 and 648 patients were enrolled, named as training set and validation set, respectively. With a median follow-up of 104.6 (interquartile, 73.1-126.9) and 51.4 (39.5-78.5) months, 31 (8.7%) and 38 (5.9%) patients in training and validation sets experienced local recurrence, and the 5-year LRFS was 93.0% and 93.2%, respectively; 63 (17.7%) and 39 (6%) patients died in training and validation sets, and the 5-year overall survival (OS) was 88.5% and 93.4%, respectively. For the whole study cohort (N=1004) with a median follow-up of 66.6 (41.5-98.0) months, the 5-year LRFS and OS was 93.2% and 91.5%. The grade 3 late toxicities included xerostomia, subcutaneous fibrosis, hearing impairment, trismus, visuality impairment and skin atrophy, with a total incidence of 1.5%. Sixty-seven of 69 (97.1%) local recurrence was in high-dose area.

Conclusion

Our individualized CTV delineation method can achieve favorable local tumor control and long-term survival outcomes with acceptable late toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小烦同学完成签到,获得积分10
刚刚
SYLH应助橙子采纳,获得20
1秒前
我是鸡汤发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
2秒前
3秒前
3秒前
科研助手6应助能干的吐司采纳,获得10
3秒前
4秒前
CipherSage应助123采纳,获得10
4秒前
4秒前
谦让之云发布了新的文献求助10
5秒前
嗯哼发布了新的文献求助10
5秒前
小蘑菇应助明亮飞双采纳,获得10
6秒前
why发布了新的文献求助10
6秒前
粥粥完成签到 ,获得积分10
6秒前
郭小宝发布了新的文献求助10
6秒前
7秒前
8秒前
白日梦完成签到,获得积分20
8秒前
8秒前
大模型应助张张张采纳,获得10
8秒前
ding应助亭亭1234采纳,获得10
9秒前
9秒前
10秒前
10秒前
11秒前
善学以致用应助苏利文采纳,获得30
12秒前
12秒前
12秒前
xmj完成签到,获得积分10
12秒前
13秒前
aaaaa发布了新的文献求助10
14秒前
123发布了新的文献求助10
16秒前
健忘傲柏完成签到,获得积分10
16秒前
顾矜应助mariawang采纳,获得10
17秒前
可爱的从寒完成签到,获得积分10
17秒前
hyx完成签到,获得积分10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021